AU Patent

AU2004305075A1 — Methods and materials for assessing prostate cancer therapies

Assigned to University of California San Diego UCSD · Expires 2005-07-07 · 21y expired

What this patent protects

Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest (2-5 fold) increase in androgen receptor (AR) mRNA was the only expression change consistently associated with developing resistance to anti-androgen therapy. Increased levels of…

USPTO Abstract

Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest (2-5 fold) increase in androgen receptor (AR) mRNA was the only expression change consistently associated with developing resistance to anti-androgen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides insight toward the design of novel anti-androgens.

Drugs covered by this patent

Patent Metadata

Patent number
AU2004305075A1
Jurisdiction
AU
Classification
—
Expires
2005-07-07
Drug substance claim
No
Drug product claim
No
Assignee
University of California San Diego UCSD
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.